Ann: Quarterly Appendix 4C and Activities Report, page-16

Having another partner for open territories de risk this company so much.

It will be two (or even more) Pharma companies who have done a deep analysis of the data and decided to invest.

In my view the risk reward ratio goes up 70%....With potential upto 1bn in milestones plus 15-20% royalties....anything less than 1bn Mc is a good buying opportunity post March results...

Just a word of caution, no one knows the outcome so there is always a chance the trial doesn't meet expectations despite all best efforts so that's why 70% risk ration is key ...